Pediatric Dermatology

FDA approves ustekinumab for pediatric psoriasis
August 07, 2020

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.

EC approves secukinumab for pediatric psoriasis
August 04, 2020

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6

Experts discuss pediatric atopic dermatitis treatments
July 24, 2020

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.